HUM trades at 38.96x earnings and 30.65x FCF despite a 6.28% ROE and a 4.67% operating margin — a valuation that assumes a margin recovery the current numbers do not support. Smart-money interest is thin (only 2 funds holding, below the Tier B threshold of 3) despite 3-quarter persistence, so this reads as Tier D — not a real institutional conviction signal. With quality score at 21.67/100 and elevated leverage (D/E 77%), the risk/reward skews unfavorable even though Health Care is nominally sector-leading this quarter.
Catalysts to watch
Medicare Advantage star-ratings and reimbursement updates over coming quarters
Potential further sell-side re-rating following recent analyst initiations (UBS, Guggenheim, Evercore)
Margin trajectory in upcoming quarterly earnings prints
Key risks
High P/E relative to single-digit ROE embeds aggressive margin-recovery expectations
Thin FCF margin (1.04%) leaves little cushion for medical-cost-ratio surprises
Elevated leverage (D/E 77%) in a capital-intensive, regulation-sensitive business
Limited institutional (13F) confirmation despite the current price level
Macro commodity overlay shows stagflation tilt (high oil, strong USD), a headwind for risk assets broadly
Not financial advice. This is the published output of an AI-driven, human-in-the-loop research process on a paper (simulated) account — informational only, not personalized investment advice, and not a solicitation to buy or sell any security. Past performance does not guarantee future results. Do your own research and trade at your own discretion in your own account. See the full disclaimer, terms & privacy.